Defining a Therapeutic Window of Opportunity in Alopecia Areata: Predictors of Early Response to Baricitinib

This study on alopecia areata (AA) examined predictors of early response to baricitinib in 44 patients, identifying that 34.1% were early responders. Key predictors for early response included a baseline Severity of Alopecia Tool (SALT) score ≤ 60%, disease duration ≤ 7 years, and elevated erythrocyte sedimentation rate (ESR) ≥ 9 mm/h. Early responders showed significant improvements in hair regrowth, quality of life, and eyebrow and eyelash density. The study suggests that using these parameters for baseline stratification can help identify patients most likely to benefit from baricitinib, indicating a therapeutic window of opportunity in AA. Despite limitations like a small sample size, the findings support personalized treatment strategies.